Abstract
Background Clade Ib, a new strain of the Clade I monkeypox virus, emerged in Eastern Democratic Republic of the Congo, sparking an international outbreak. Comprehensive studies are needed to assess its transmission dynamics and clinical presentation.
Methods We conducted a prospective observational cohort study at Kamituga General Hospital in South Kivu, DRC, between May 2 and October 9, 2024. Sociodemographic, exposure and clinical data were collected from mpox suspected cases. Cases confirmed by Xpert® Mpox PCR were presumed Clade Ib infections (awaiting Clade confirmation) and followed through hospitalization and on days 29 and 59 post-diagnosis to assess clinical progression and outcomes.
Findings Of 511 included suspected cases, 431 (84%) tested PCR positive; with 205 being women (47%). Age distribution was bimodal, with 279 (65%) individuals aged 15-34 years, and 63 (15%) children under five. Most cases (59%) reported contact with a suspected or confirmed mpox case; among adults, this was primarily a spouse, colleague or sexual partner, while for children, the primary contacts were parents or siblings. Comorbidities were rare (4%), including six (1%) HIV infections. Prodromal symptoms were present in 346 (88%) patients, active skin lesions in 414 (96%), mucosal lesions in 338 (82%), and lymphadenopathy in 295 (71%). In adults, lesions were more concentrated in the genital area, with 90% of adults presenting lesions in this region. In contrast, only 39% of children had genital lesions, with lesions more frequently found elsewhere on the body. Among 427 hospitalized patients, two deaths (0·5%) occurred. Among 315 patients with detailed hospital follow-up, complications were primarily genito-urinary (55%) or cutaneous (40%). Four of six pregnant women with recorded outcome (67%) had adverse pregnancy outcomes. Significant sequelae at days 29 and 59 were rare.
Interpretation Clade Ib MPXV infections presented differently from previously reported Clade Ia and Clade IIb infections. In adults, the disease primarily affected the genito-urinary system, compatible with sexual transmission, while children mostly manifested extragenital lesions.
Funding European & Developing Countries Clinical Trials Partnership (EDCTP2 and EDCTP3); Belgian Directorate-General Development Cooperation and Humanitarian Aid; Research Foundation – Flanders
Competing Interest Statement
LL has consulted for BioNtech and received research funding from Sanofi, both not relevant for this work. All other authors declare no conflict of interest.
Clinical Trial
NCT06652646
Funding Statement
This work was funded by the Belgian Directorate-General Development Cooperation and Humanitarian Aid and the European and Developing Countries Clinical Trials Partnership EDCTP3 (grant number 101195465). Additional support was provided by the Research Foundation Flanders (FWO, grant number G096222N to EBo, LL, JJM and 12B1M24N to CVD) and through the African coaLition for Epidemic Research, Response and Training (ALERRT) network. ALERRT is part of the EDCTP2 Programme supported by the European Union under grant agreement RIA2016E-1612. ALERRT is also supported by the United Kingdom National Institute for Health Research. EBa, EDV, and IB are members of the Institute of Tropical Medicine Outbreak Research Team, financially supported by the Department of Economy, Science, and Innovation of the Flemish government (EWI). The funders had no role in the conceptualization of the study, data acquisition or interpretation, writing of the manuscript, or publication of the findings.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the University of Kinshasa (approval ID ESP/CE/78/2024) and the Ethics Committee of the University Hospital Antwerp (ID 6383). Written consent was obtained prior to all study procedures from participants aged 18 years and older, and from parents or guardians for minors. Children from 12 to 17 years old received age-appropriate information and signed an assent form. Pictures for publication were taken with additional written consent. All participants received reimbursement of transportation costs for visits and free care and nutrition.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
